Published in Future Oncol on January 01, 2015
Targeting Autophagy for Oncolytic Immunotherapy. Biomedicines (2017) 0.79
Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach. PLoS One (2017) 0.75
The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. J Virol (2004) 2.32
Innate cellular response to virus particle entry requires IRF3 but not virus replication. J Virol (2004) 1.91
The IFN-independent response to virus particle entry provides a first line of antiviral defense that is independent of TLRs and retinoic acid-inducible gene I. J Immunol (2006) 1.52
Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol (2007) 1.32
Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses. PLoS One (2010) 1.28
Varicella-zoster virus immediate-early protein ORF61 abrogates the IRF3-mediated innate immune response through degradation of activated IRF3. J Virol (2011) 1.24
Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response. J Interferon Cytokine Res (2009) 1.24
Recent advances in understanding viral evasion of type I interferon. Immunology (2013) 1.22
Identification of a novel pathway essential for the immediate-early, interferon-independent antiviral response to enveloped virions. J Virol (2006) 1.21
Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol (2007) 1.17
Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. J Virol (2006) 1.16
Innate and adaptive immune responses to herpes simplex virus. Viruses (2009) 1.14
Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5. J Virol (2012) 1.14
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2010) 1.12
Recognition of virus infection and innate host responses to viral gene therapy vectors. Mol Ther (2010) 1.10
FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. PLoS Pathog (2008) 1.06
Functional inaccessibility of quiescent herpes simplex virus genomes. Virol J (2005) 1.06
An accessory to the 'Trinity': SR-As are essential pathogen sensors of extracellular dsRNA, mediating entry and leading to subsequent type I IFN responses. PLoS Pathog (2010) 1.06
Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol Res (2013) 1.05
Membrane perturbation elicits an IRF3-dependent, interferon-independent antiviral response. J Virol (2011) 1.05
The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther (2005) 1.02
Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One (2010) 1.01
MARCO is required for TLR2- and Nod2-mediated responses to Streptococcus pneumoniae and clearance of pneumococcal colonization in the murine nasopharynx. J Immunol (2012) 1.01
Cigarette smoke suppresses type I interferon-mediated antiviral immunity in lung fibroblast and epithelial cells. J Interferon Cytokine Res (2008) 0.99
Characterization of the interferon regulatory factor 3-mediated antiviral response in a cell line deficient for IFN production. Mol Immunol (2008) 0.99
Long double-stranded RNA induces an antiviral response independent of IFN regulatory factor 3, IFN-beta promoter stimulator 1, and IFN. J Immunol (2009) 0.97
IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res (2011) 0.97
HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium. J Immunol (2013) 0.96
ICP0 prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cells. J Virol (2006) 0.94
Differential modification of interferon regulatory factor 3 following virus particle entry. J Virol (2009) 0.94
The herpes simplex virus 1-encoded envelope glycoprotein B activates NF-κB through the Toll-like receptor 2 and MyD88/TRAF6-dependent signaling pathway. PLoS One (2013) 0.87
A critical role for IL-15 in TLR-mediated innate antiviral immunity against genital HSV-2 infection. Immunol Cell Biol (2011) 0.86
Cigarette smoke attenuation of poly I:C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFN-beta production. Mol Immunol (2008) 0.85
The nitric oxide pathway provides innate antiviral protection in conjunction with the type I interferon pathway in fibroblasts. PLoS One (2012) 0.83
Proinflammatory cytokines and chemokines - but not interferon-β - produced in response to HSV-2 in primary human genital epithelial cells are associated with viral replication and the presence of the virion host shutoff protein. Am J Reprod Immunol (2013) 0.81
Novel paradigms of innate immune sensing of viral infections. Cytokine (2013) 0.80
Extracellular dsRNA: its function and mechanism of cellular uptake. J Interferon Cytokine Res (2014) 0.79
Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I:C-augmented human PBMCs. Mol Immunol (2009) 0.78
Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer. Mol Cancer (2013) 0.77
Restoration of vitamin C synthesis in transgenic Gulo-/- mice by helper-dependent adenovirus-based expression of gulonolactone oxidase. Hum Gene Ther (2008) 0.76
Interferon-Dependent Induction of Clr-b during Mouse Cytomegalovirus Infection Protects Bystander Cells from Natural Killer Cells via NKR-P1B-Mediated Inhibition. J Innate Immun (2017) 0.75